Takeda Pharmaceutical Company plans to invest EUR 25 million ($30 million) to construct a new regenerative medicine facility at its site in Grange Castle, Dublin, Ireland.

The investment will expand the Grange Castle site with the construction of a new stand-alone modular cell-therapy facility dedicated to manufacturing a stem-cell therapy. The facility will begin commercial operation by 2021. The investment is also expected to create 70 temporary construction jobs. 

In 2002, Takeda chose Dublin as the location for its first active pharmaceutical ingredient facility outside of Japan. In 2017, Takeda announced a EUR 40-million ($49-million) investment for the construction of a stand-alone production facility for manufacturing part of its oncology portfolio at Grange Castle.

Source: IDA Ireland